- Home
- IVA vs KALV Comparison
IVA vs KALV Comparison
Compare IVA & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVA
- KALV
- Stock Information
- Founded
- IVA 2011
- KALV N/A
- Country
- IVA France
- KALV United States
- Employees
- IVA N/A
- KALV N/A
- Industry
- IVA Biotechnology: Pharmaceutical Preparations
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- IVA Health Care
- KALV Health Care
- Exchange
- IVA Nasdaq
- KALV Nasdaq
- Market Cap
- IVA 769.0M
- KALV 796.4M
- IPO Year
- IVA 2020
- KALV N/A
- Fundamental
- Price
- IVA $6.24
- KALV $10.96
- Analyst Decision
- IVA Strong Buy
- KALV Strong Buy
- Analyst Count
- IVA 7
- KALV 8
- Target Price
- IVA $16.00
- KALV $26.43
- AVG Volume (30 Days)
- IVA 61.2K
- KALV 1.5M
- Earning Date
- IVA 09-29-2025
- KALV 09-11-2025
- Dividend Yield
- IVA N/A
- KALV N/A
- EPS Growth
- IVA N/A
- KALV N/A
- EPS
- IVA N/A
- KALV N/A
- Revenue
- IVA $19,929,536.00
- KALV $1,426,000.00
- Revenue This Year
- IVA N/A
- KALV N/A
- Revenue Next Year
- IVA N/A
- KALV $213.43
- P/E Ratio
- IVA N/A
- KALV N/A
- Revenue Growth
- IVA N/A
- KALV N/A
- 52 Week Low
- IVA $1.60
- KALV $7.30
- 52 Week High
- IVA $6.55
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- IVA 60.61
- KALV 27.85
- Support Level
- IVA $5.59
- KALV $11.93
- Resistance Level
- IVA $6.55
- KALV $12.43
- Average True Range (ATR)
- IVA 0.33
- KALV 0.60
- MACD
- IVA 0.01
- KALV -0.22
- Stochastic Oscillator
- IVA 78.02
- KALV 6.17
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.